Agios Pharmaceuticals Inc. (NASDAQ:AGIO) Shares Fall 10% On Weak fourth quarter Earnings Print E-mail
By Josh Gee   
Tuesday, 17 February 2015 15:53

Shares of Agios Pharmaceuticals Inc. (NASDAQ:AGIO) are down $10 or $8.30% to $108.60 on hefty volume after the company posted a worse than expected fourth quarter results this morning.

The company on Tuesday posted a net loss of $26.7 million in its latest quarter. The Cambridge, Massachusetts-based company said it had a loss of 76 cents a share.

The results missed the Wall Street expectations. The average estimate of analysts surveyed by Zacks Investment Research was for a loss of 55 cents per share.

The biopharmaceutical company reported revenue of $14.6 million in the period, surpassing Street forecasts. Analysts expected $11.6 million, according to Zacks.

For the year, the company reported that its loss jumped to $53.5 million, or $1.59 per share. Revenue was reported as $65.4 million.

Shares of the company are down 2% so far this year. Over the past one year, the stock has been trading within a range of $28.81 and $138.85. Over the past one year, shares of the company have outperformed the wider market and jumped 240%.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is intend to apply its deep understanding of metabolism, coupled with the Company’s ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and inborn errors of metabolism (IEMs) are treated. The Company has identified and validated novel and druggable targets in both cancer and IEMs.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter